UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2022
Global Blood Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37539 | 27-4825712 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
181 Oyster Point Blvd.
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 741-7700
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock, par value $0.001 per share | GBT | The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
In this report, “GBT,” “Company,” “we,” “our,” and “us” means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The proposals set forth below were submitted to the stockholders at the 2022 Annual Meeting of Stockholders, or Annual Meeting, of Global Blood Therapeutics, Inc., held on June 14, 2022, with each such proposal described in our definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2022, or Proxy Statement.
The number of shares of common stock entitled to vote at the Annual Meeting was 65,098,164. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 54,401,804. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.
Proposal 1 – Election of Directors
Our stockholders elected the Class I director nominees below to our Board of Directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
| Director Nominee |
Votes For |
Votes Withheld | ||
| Ted W. Love, M.D. |
40,144,676 | 8,585,291 | ||
| Glenn F. Pierce, M.D., Ph.D. |
40,352,391 | 8,377,576 | ||
| Dawn A. Svoronos |
29,383,996 | 19,345,971 |
There were 5,671,837 broker non-votes regarding this proposal.
Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers as Disclosed in the Proxy Statement
Our stockholders approved, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.
| Votes For |
Votes Against |
Abstentions | ||
| 46,274,486 |
2,435,500 | 19,981 |
There were 5,671,837 broker non-votes regarding this proposal.
Proposal 3 – Ratification of Appointment of Independent Registered Accounting Firm
Our stockholders ratified the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
| Votes For |
Votes Against |
Abstentions | ||
| 54,244,583 |
142,281 | 14,940 |
There were no broker non-votes regarding this proposal.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Global Blood Therapeutics, Inc. | ||||||
| Date: June 15, 2022 | By: | /s/ Jeffrey Farrow | ||||
| Jeffrey Farrow | ||||||
| Chief Financial Officer | ||||||